Abstract
Energy-based tumor ablative techniques are under development for the minimally invasive treatment of renal cell carcinoma. Radiofrequency ablation has recently entered phase II clinical trials for the treatment of small renal tumors. The authors review the status of these clinical trials. Radiofrequency ablation has shown reproducible tumor destruction in both animal models and recent clinical trials. Radiographic follow-up of radiofrequency ablated small renal tumors demonstrates little or no residual contrast enhancement depending on tumor size, location within the kidney, and mode of delivering radiofrequency energy. Pathologic evaluation of ablated tumors shows more variability in outcome, with many tumors demonstrating small areas of viable residual tumor. Radiofrequency ablation shows promise for the minimally invasive treatment of small renal tumors but will remain experimental until the resolution of certain technical issues.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
